Bencyclane

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bencyclane
Accession Number
DB13488
Type
Small Molecule
Groups
Experimental
Description

A vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects. Its mechanism may involve block of calcium channels.

Structure
Thumb
Synonyms
  • 3-((1-Benzylcycloheptyl)oxy)-N,N-dimethylpropylamin
  • Benciclano
  • Bencyclanum
Product Ingredients
IngredientUNIICASInChI Key
Bencyclane fumarateOZN2MG334O14286-84-1LSTKNZAMFRGXCG-WLHGVMLRSA-N
Categories
UNII
6I97Z6S135
CAS number
2179-37-5
Weight
Average: 289.463
Monoisotopic: 289.240564622
Chemical Formula
C19H31NO
InChI Key
FYJJXENSONZJRG-UHFFFAOYSA-N
InChI
InChI=1S/C19H31NO/c1-20(2)15-10-16-21-19(13-8-3-4-9-14-19)17-18-11-6-5-7-12-18/h5-7,11-12H,3-4,8-10,13-17H2,1-2H3
IUPAC Name
{3-[(1-benzylcycloheptyl)oxy]propyl}dimethylamine
SMILES
CN(C)CCCOC1(CC2=CC=CC=C2)CCCCCC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Bencyclane.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Bencyclane.Vet Approved
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Bencyclane.Approved, Vet Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Bencyclane.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Bencyclane.Approved
AmobarbitalThe metabolism of Bencyclane can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Bencyclane.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Bencyclane.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Bencyclane.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Bencyclane.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Bencyclane.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Bencyclane.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Bencyclane.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Bencyclane.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Bencyclane.Experimental
BarbexacloneThe metabolism of Bencyclane can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Bencyclane can be increased when combined with Barbital.Illicit
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Bencyclane.Approved, Investigational
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Bencyclane.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Bencyclane.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Bencyclane.Experimental
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Bencyclane.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Bencyclane.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Bencyclane.Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Bencyclane.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Bencyclane.Approved
Calcium AcetateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Bencyclane.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Bencyclane.Experimental
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Bencyclane.Approved, Investigational
CaseinThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Bencyclane.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Bencyclane.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Bencyclane.Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Bencyclane.Approved, Investigational, Vet Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Bencyclane.Approved, Investigational
CimetidineThe serum concentration of Bencyclane can be increased when it is combined with Cimetidine.Approved, Investigational
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bencyclane.Approved
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Bencyclane.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Bencyclane.Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Bencyclane.Investigational
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Bencyclane.Approved, Investigational, Vet Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Bencyclane.Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Bencyclane.Approved, Illicit
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Bencyclane.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Bencyclane.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Bencyclane.Approved, Investigational
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Bencyclane.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Bencyclane.Approved, Vet Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Bencyclane.Approved
EfavirenzThe serum concentration of Bencyclane can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Bencyclane.Approved
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Bencyclane.Approved, Vet Approved
EscitalopramThe risk or severity of hypotension can be increased when Escitalopram is combined with Bencyclane.Approved, Investigational
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Bencyclane.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Bencyclane.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Bencyclane.Approved, Investigational
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Bencyclane.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Bencyclane.Experimental
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Bencyclane.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Bencyclane.Approved, Investigational, Vet Approved
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Bencyclane.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Bencyclane.Approved, Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Bencyclane.Approved, Investigational
HexobarbitalThe metabolism of Bencyclane can be increased when combined with Hexobarbital.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Bencyclane.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Bencyclane.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Bencyclane.Withdrawn
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Bencyclane.Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Bencyclane.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Bencyclane.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Bencyclane.Approved
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Bencyclane.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Bencyclane is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Bencyclane is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Bencyclane is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Bencyclane is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Bencyclane.Experimental
MethohexitalThe metabolism of Bencyclane can be increased when combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Bencyclane.Approved, Investigational
MethylphenobarbitalThe metabolism of Bencyclane can be increased when combined with Methylphenobarbital.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Bencyclane.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Bencyclane.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Bencyclane.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Bencyclane.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Bencyclane.Vet Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Bencyclane.Experimental
NafcillinThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Bencyclane.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Bencyclane.Approved
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Bencyclane.Approved, Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Bencyclane.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Bencyclane.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Bencyclane.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Bencyclane.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Bencyclane.Investigational
NitroprussideBencyclane may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Bencyclane.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Bencyclane.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Bencyclane.Approved, Vet Approved
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Bencyclane.Approved, Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Bencyclane.Experimental
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Bencyclane.Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Bencyclane.Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Bencyclane.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Bencyclane.Approved, Investigational
PentobarbitalThe metabolism of Bencyclane can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe metabolism of Bencyclane can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Bencyclane.Approved
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Bencyclane.Approved
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Bencyclane.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Bencyclane.Approved, Investigational, Vet Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Bencyclane.Approved
PrimidoneThe metabolism of Bencyclane can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Bencyclane.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Bencyclane.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Bencyclane.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Bencyclane.Approved, Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Bencyclane.Experimental
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Bencyclane.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Bencyclane.Approved, Investigational
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Bencyclane.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Bencyclane.Experimental
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Bencyclane.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Bencyclane.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Bencyclane.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Bencyclane.Approved, Investigational
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Bencyclane.Approved, Investigational
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Bencyclane.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Bencyclane.Approved, Investigational, Vet Approved
SecobarbitalThe metabolism of Bencyclane can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Bencyclane.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Bencyclane.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Bencyclane.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Bencyclane.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Bencyclane.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Bencyclane.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Bencyclane.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Bencyclane.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Bencyclane.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Bencyclane.Approved
ThiamylalThe metabolism of Bencyclane can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Bencyclane can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Bencyclane.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Bencyclane.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Bencyclane.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Bencyclane.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Bencyclane.Approved, Vet Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Bencyclane.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Bencyclane.Approved, Investigational, Vet Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Bencyclane.Approved, Investigational
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Bencyclane.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Bencyclane.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Bencyclane.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Bencyclane.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Bencyclane.Investigational
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Bencyclane.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Bencyclane.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Bencyclane.Experimental
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Bencyclane.Approved
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Bencyclane.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
2222
ChEBI
135205
ChEMBL
CHEMBL2110767
Wikipedia
Bencyclane
ATC Codes
C04AX11 — Bencyclane

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000361 mg/mLALOGPS
logP5.07ALOGPS
logP4.38ChemAxon
logS-5.9ALOGPS
pKa (Strongest Basic)9.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity90.77 m3·mol-1ChemAxon
Polarizability35.88 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Trialkylamines / Dialkyl ethers / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Tertiary aliphatic amine / Tertiary amine / Ether / Dialkyl ether / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:43 / Updated on July 02, 2018 21:00